As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Feature|Articles|October 9, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
The Future of Precision Medicine Depends on More Than Biology
Author(s)Ben Hargreaves
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of biological targets allowed developers to design molecules that acted more precisely, as the evolution of JAK inhibitors for autoimmune disease in particular has demonstrated.
Related to this article
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement